Home・Aktien・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Geschlossen

4.88 2.95

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.78

Max

4.9

Schlüsselkennzahlen
By Trading Economics
Einkommen	-136K -35M
EPS	-0.503
Angestellte	106
EBITDA	2.2M -35M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+31.15% upside

Dividenden
By Acuity
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	41M 336M
Vorheriger Eröffnungskurs	1.93
Vorheriger Schlusskurs	4.88

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Juli 2026, 23:51 UTC

Cryptocurrency declines amid cautious investor sentiment ahead of key inflation data and geopolitical tensions impacting U.S. markets.

11. Juli 2026, 23:51 UTC

Cryptocurrency prices dip amid geopolitical tensions and cautious investor sentiment ahead of key U.S. inflation reports.

11. Juli 2026, 23:51 UTC

U.S. Stocks Rise Amid AI Enthusiasm and Geopolitical Tensions; Key Inflation Data and China's Declining Retail Sales Loom Ahead.

11. Juli 2026, 23:51 UTC

Cryptocurrency market dips as Bitcoin and Ethereum decline, while U.S. stocks rise ahead of key inflation data and China's retail sales forecast shows potential consumer spending weakness.

11. Juli 2026, 23:51 UTC

Mixed sentiment ahead of NAB Business Confidence report release on July 14, amid ongoing economic concerns and geopolitical uncertainties in Australia.

11. Juli 2026, 23:51 UTC

Correlated Moves

Bitcoin is lower during Saturday's session, continuing a decline since Friday's close. Volatility included a session high earlier before pulling back.

11. Juli 2026, 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Decline 0.1% in June Amid Weakening Consumer Spending and Economic Uncertainty

11. Juli 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Release on July 16, 2026, Amid Cautious Market Sentiment Due to Geopolitical Tensions and Upcoming Economic Data.

11. Juli 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.3% in June Amid Strong Consumer Spending Trends, According to Bank of America Report

11. Juli 2026, 23:31 UTC

Canada's Housing Starts Data for June 2026 Expected at 260K Amid Economic Volatility and Affordability Concerns.

11. Juli 2026, 23:21 UTC

U.S. Core Producer Prices Expected to Rise 0.4% in June Amid Mixed Global Inflation Signals and Economic Uncertainties

11. Juli 2026, 23:21 UTC

Cautious Market Sentiment Ahead of July 15 Release of NY Empire State Manufacturing Index Amid Geopolitical Tensions and Earnings Reports

11. Juli 2026, 23:21 UTC

Producers Price Inflation (PPI) MoM for June 2026 set to release on July 15, with a forecasted increase of 0.2%, influencing potential Federal Reserve interest rate decisions amid ongoing inflation concerns.

11. Juli 2026, 23:11 UTC

Brazil's Retail Sales Report on July 16, 2026, Expected to Show Volatility Amid Economic Uncertainty and Mixed Previous Results.

11. Juli 2026, 23:01 UTC

Investors Cautiously Await U.S. Core Inflation Rate Release Amid Geopolitical Tensions and Earnings Uncertainty

11. Juli 2026, 23:01 UTC

Upcoming U.S. CPI Release on July 14 Sparks Caution Among Investors Amid Inflation Concerns and Geopolitical Tensions

11. Juli 2026, 23:01 UTC

Investors Brace for July 14 CPI Release Amid High Inflation Concerns and Potential Fed Rate Hike

11. Juli 2026, 23:01 UTC

Investors Brace for July CPI Release Amid Inflation Concerns and Market Volatility

11. Juli 2026, 23:01 UTC

US Core Inflation Rate Expected to Rise 0.3% in June Amid Market Caution and Geopolitical Tensions

11. Juli 2026, 23:01 UTC

U.S. Inflation Rate Expected to Decrease Slightly in June Amid Cautious Market Sentiment and Geopolitical Tensions

11. Juli 2026, 23:01 UTC

Correlated Moves

The Dow Jones Index declined during after-market hours, reflecting cumulative weakness since Friday's close amid broader market sentiment.

11. Juli 2026, 22:53 UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid optimistic market sentiment following positive employment figures and easing geopolitical tensions.

11. Juli 2026, 22:53 UTC

Australia's Westpac Consumer Confidence report on July 14, 2026, is expected to show improvement amid positive stock market gains and ongoing inflation concerns.

11. Juli 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Release on July 15 Expected to Reflect Ongoing Inflation and Geopolitical Tensions Impacting Market Sentiment.

11. Juli 2026, 22:31 UTC

Brazil's Central Bank to Provide Key Interest Rate Outlook on July 13, Amid Global Inflationary Trends.

11. Juli 2026, 22:31 UTC

Japan's Machinery Orders Expected to Decline by 4.2% in May Amid Mixed Economic Sentiment and Geopolitical Tensions

11. Juli 2026, 22:21 UTC

Singapore's Upcoming GDP Growth Rate Release Sparks Cautious Optimism Amid Regional Market Trends and Global Economic Factors

11. Juli 2026, 21:41 UTC

South Korea's Unemployment Rate Release on July 14 Expected to Show Increase Amid Economic Concerns and Job Losses.

11. Juli 2026, 21:31 UTC

UK Retail Sales Monitor YoY Forecasts 2.9% Growth Amid Mixed Sentiment and Geopolitical Concerns Ahead of July Release

11. Juli 2026, 20:41 UTC

India's June 2026 Inflation Rate Expected at 4.3%, Amid Rising Prices and Geopolitical Concerns

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

31.15% Vorteil

12-Monats-Prognose

Durchschnitt 6.4 USD 31.15%

Hoch 10 USD

Tief 4 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Zentalis Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.